Lupin Aims To Be In The First Wave Of GLP-1s In Emerging Markets

Also, Discusses Upcoming US Injectables Launches And Its Position In Biosimilars Race

 
• By Urtė Fultinavičiūtė

With most regions reporting double-digit growth in the second quarter, analysts’ opinions differ about Lupin’s future.

Businessman surfing on waves as upward arrow.
(Shutterstock)

More from Earnings

More from Generics Bulletin